FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients with PD-L1 expression <1% did not show improved PFS when atezolizumab was added to nab-paclitaxel (HR of 0.94, 95% CI 0.78, 1.13).
Croatian: U bolesnika s ekspresijom PD-L1 < 1% nije opaženo produljenje PFS-a kada je atezolizumab dodan nab-paklitakselu (HR: 0,94; 95% CI: 0,78; 1,13).
English: Patients should be monitored for signs and symptoms of myocarditis.
Croatian: Bolesnike treba nadzirati zbog moguće pojave znakova i simptoma miokarditisa.
English: For the recommended dose of 840 mg: fourteen mL of Tecentriq concentrate should be withdrawn from the vial and diluted into a 250 mL polyvinyl chloride (PVC), polyolefin (PO), polyethylene (PE), or polypropylene (PP) infusion bag containing sodium chloride 9 mg/mL (0.9%) solution for injection.
Croatian: Za preporučenu dozu od 840 mg: Potrebno je izvući 14 ml koncentrata lijeka Tecentriq iz bočice i razrijediti ga ubrizgavanjem u polivinilkloridnu (PVC), poliolefinsku (PO), polietilensku (PE) ili polipropilensku (PP) infuzijsku vrećicu volumena 250 ml koja sadrži otopinu natrijeva klorida za injekciju od 9 mg/ml (0,9%).
English: • inflammation of the intestines (colitis): symptoms may include diarrhoea (watery, loose or soft stools), blood in stools, and stomach pain
Croatian: • upalu crijeva (kolitis): simptomi mogu uključivati proljev (vodenaste ili meke stolice), krv u stolici i bol u trbuhu
English: • inflammation of the lung (pneumonitis): symptoms may include new or worsening cough, shortness of breath, and chest pain
Croatian: • upalu pluća (pneumonitis): simptomi mogu uključivati pojavu ili pogoršanje kašlja, nedostatak zraka i bol u prsnom košu
English: Rash
Croatian: Roche
English: For all treated patients, the median duration of treatment was 2.1 months for the docetaxel arm and 3.4 months for the atezolizumab arm.
Croatian: Medijan trajanja liječenja među svim liječenim bolesnicima iznosio je 2,1 mjesec u skupini liječenoj docetakselom te 3,4 mjeseca u skupini liječenoj atezolizumabom.
English: Hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis and type 1 diabetes mellitus, including diabetic ketoacidosis have been observed in clinical trials with atezolizumab (see section
Croatian: U kliničkim ispitivanjima atezolizumaba primijećeni su hipotireoza, hipertireoza, insuficijencija nadbubrežne žlijezde, hipofizitis i šećerna bolest tipa 1, uključujući dijabetičku ketoacidozu (vidjeti dio 4.8).
English: The median time to onset was 1.5 months (range 6 days to 18.8
Croatian: Medijan vremena do nastupa iznosio je 1,5 mjeseci (raspon od 6 dana do 18,8 mjeseci).
English: Treatment with insulin should be initiated for type 1 diabetes mellitus.
Croatian: U slučaju šećerne bolesti tipa 1 treba uvesti liječenje inzulinom.
English: Tel: +371 - 6 7039831
Croatian: Roche Latvija SIA Tel: +371 - 6 7039831
English: Table 9: Summary of efficacy from IMpower130 in the primary analysis (ITT-WT population) Efficacy endpoints
Croatian: Tablica 9: Sažetak rezultata za djelotvornost u primarnoj analizi podataka iz ispitivanja IMpower130 (ITT populacija s tumorom divljeg tipa)
English: The median duration was 8.0 months (range 18 days to 8.3+ months; + denotes a censored value).
Croatian: Medijan trajanja iznosio je 8,0 mjeseci (raspon od 18 dana do 8,3+ mjeseca; ‘+' označava cenzuriranu vrijednost).
English: Figure 7: Forest plot of overall survival by PD-L1 expression (IMpower130)
Croatian: Slika 7: Grafikon raspona pouzdanosti za ukupno preživljenje prema ekspresiji PD-L1 (IMpower130)
English: Figure 4: Kaplan-Meier curve for PFS in the ITT population (IMpower150)
Croatian: Slika 4: Kaplan-Meierova krivulja PFS-a u ITT populaciji (IMpower150)
English: IMvigor211 (GO29294): Randomised trial in locally advanced or metastatic UC patients previously treated with chemotherapy
Croatian: IMvigor211 (GO29294): Randomizirano ispitivanje u bolesnika s lokalno uznapredovalim ili metastatskim urotelnim karcinomom prethodno liječenih kemoterapijom
English: Per second interim analysis for OS and exploratory PFS analysis at clinical cut off January 2
Croatian: 4 Prema drugoj interim analizi OS-a i eksploracijskoj analizi PFS-a; završni datum prikupljanja kliničkih podataka 2. siječnja 2019.
English: One patient required the use of corticosteroids and treatment with atezolizumab was discontinued.
Croatian: U jednog je bolesnika bila potrebna primjena kortikosteroida i prekinuto je liječenje atezolizumabom.
English: and 0.82 for OS while in patients who had not received prior (neo)adjuvant treatment (n=127), the hazard ratio for PFS was 0.44 and 0.53 for OS.
Croatian: Među bolesnicima koji su prethodno primali (neo)adjuvantno liječenje (n=242) omjer hazarda za PFS iznosio je 0,79, a za OS 0,82, dok je u bolesnika koji prethodno nisu primali (neo)adjuvantno liječenje (n=127) omjer hazarda za PFS iznosio 0,44, dok je OS iznosio 0,53.
English: The demographic and baseline disease characteristics of the primary analysis population were well balanced between the treatment arms.
Croatian: Demografske i početne značajke bolesti u populaciji za primarnu analizu bile su dobro ujednačene između liječenih skupina.
English: For Grade 2 or Grade 3 hypophysitis, atezolizumab should be withheld and treatment with intravenous corticosteroids (1 to 2 mg/kg/day methylprednisolone or equivalent) should be started, and hormone replacement should be initiated as needed.
Croatian: U slučaju hipofizitisa 2. ili 3. stupnja treba odgoditi primjenu atezolizumaba i uvesti liječenje intravenskim kortikosteroidima (1 - 2 mg/kg/dan metilprednizolona ili ekvivalenta), a po potrebi i hormonsko nadomjesno liječenje.
English: After dilution (see section 6.6), one mL of solution contains approximately 3.2 mg of atezolizumab for the 840 mg dose and approximately 6.0 mg of atezolizumab for the 1680 mg dose.
Croatian: Nakon razrjeđivanja (vidjeti dio 6.6) jedan ml otopine sadrži približno 3,2 mg atezolizumaba za dozu od 840 mg, odnosno približno 6,0 mg atezolizumaba za dozu od 1680 mg.
English: For each 21-day cycle, Tecentriq, nab-paclitaxel, and carboplatin are administered on day 1.
Croatian: Tecentriq, nab-paklitaksel i karboplatin primjenjuju se 1. dana svakog 21-dnevnog ciklusa.
English: Grade 2 or 3 Diarrhoea (increase of ≥ 4
Croatian: Proljev 2. ili 3. stupnja (povećanje za ≥ 4 stolice/dan u odnosu na početnu vrijednost)
English: Figure 3: Forest plot of overall survival by PD-L1 expression in the ITT population, Arm B vs. C (IMpower150)
Croatian: Slika 3: Grafikon raspona pouzdanosti (engl. forest plot) za ukupno preživljenje prema ekspresiji PD-L1 u ITT populaciji, skupina B naspram skupine C (IMpower150)
English: The median duration was 2.8 months (range 15 days to 9.5+ months; + denotes a censored value).
Croatian: Medijan trajanja iznosio je 2,8 mjeseci (raspon od 15 dana do 9,5+ mjeseci; ‘+' označava cenzuriranu vrijednost).
English: • inflammation of the pituitary gland situated at the base of the brain
Croatian: • upala hipofize (žlijezde smještene na bazi mozga)
English: The key results in the all comer population are summarised in Table 3.
Croatian: Ključni rezultati u populaciji svih uključenih bolesnika sažeto su prikazani u Tablici
English: There were 310 patients treated with atezolizumab 1,200 mg by intravenous infusion every 3 weeks until loss of clinical benefit.
Croatian: Kohorta 2 uključivala je 310 bolesnika koji su liječeni atezolizumabom u dozi od 1200 mg primijenjenim intravenskom infuzijom svaka 3 tjedna do gubitka kliničke koristi.
English: Thyroid function should be monitored prior to and periodically during treatment with atezolizumab.
Croatian: Funkciju štitnjače treba provjeriti prije početka liječenja atezolizumabom i kontrolirati periodički tijekom liječenja.
English: Treatment may be resumed if the event improves to ≤ Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day and the patient is stable on replacement therapy (if required).
Croatian: Liječenje se može nastaviti ako se događaj poboljša do ≤ 1. stupnja unutar 12 tjedana, doza kortikosteroida smanji na ≤ 10 mg prednizona ili ekvivalenta na dan, a bolesnikovo stanje stabilizira nadomjesnom terapijom (ako je to potrebno).
English: 1-year OS rate (%)
Croatian: Stopa 1-godišnjeg OS-a (%)
English: Common abdominal pain, colitiss, dysphagia, oropharyngeal paint stomatitis, dysgeusia
Croatian: Često bol u abdomenu, kolitis s, disfagija, bol u usnoj šupljini i ždrijelut stomatitis, disgeuzija
English: Tecentriq 840 mg concentrate for solution for infusion atezolizumab
Croatian: Tecentriq 840 mg koncentrat za otopinu za infuziju atezolizumab
English: Arm B Nab-paclitaxel + carboplatin
Croatian: Skupina B Nab-paklitaksel + karboplatin
English: There was no evidence of efficacy in patients with asymptomatic brain metastases at baseline, although the number of patients treated was small; the median PFS was 2.2 months in the atezolizumab plus nab-paclitaxel arm (n=15) compared to 5.6 months in the placebo plus nabpaclitaxel arm (n=11) (HR 1.40; 95% CI 0.57, 3.44).
Croatian: Medijan PFS-a iznosio je 2,2 mjeseca u skupini liječenoj atezolizumabom plus nab-paklitakselom (n=15) u odnosu na 5,6 mjeseci u skupini koja je primala placebo plus nab-paklitaksel (n=11) (HR: 1,40; 95% CI: 0,57; 3,44).
English: Sucrose
Croatian: Hrvatska
English: Figure 10: Kaplan-Meier curve for overall survival in the primary analysis population (all comers) (OAK)
Croatian: Slika 10: Kaplan-Meierova krivulja ukupnog preživljenja u populaciji za primarnu analizu (svi uključeni bolesnici) (OAK)
English: No. of complete response (%) No. of partial response (%) No. of stable disease (%)
Croatian: Broj bolesnika s potpunim odgovorom (%) Broj bolesnika s djelomičnim odgovorom (%) Broj bolesnika sa stabilnom bolešću (%) Trajanje odgovora prema ocjeni ispitivača
English: A phase III, open-label, multi-center, international, randomised study, (IMvigor211), was conducted to evaluate the efficacy and safety of atezolizumab compared with chemotherapy (investigator's choice of vinflunine, docetaxel, or paclitaxel) in patients with locally advanced or metastatic UC who progressed during or following a platinum-containing regimen.
Croatian: Otvoreno, multicentrično, međunarodno, randomizirano ispitivanje faze III (IMvigor211) provedeno je radi ocjene djelotvornosti i sigurnosti atezolizumaba u odnosu na kemoterapiju (vinflunin, docetaksel ili paklitaksel, prema izboru ispitivača) u bolesnika s lokalno uznapredovalim ili metastatskim urotelnim karcinomom (UK) kojima je bolest uznapredovala tijekom ili nakon liječenja protokolom koji je sadržavao platinu.
English: Patients who were administered a live, attenuated vaccine within 28 days prior to enrolment; systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medicinal products within 2 weeks prior to study entry were excluded from clinical trials.
Croatian: Bolesnici koji su primili živo atenuirano cjepivo unutar 28 dana prije uključivanja u ispitivanje, sistemske imunostimulatore unutar 4 tjedna prije uključivanja u ispitivanje ili sistemske imunosupresive unutar 2 tjedna prije uključivanja u ispitivanje nisu mogli sudjelovati u kliničkim ispitivanjima.
English: Tecentriq 1,200 mg concentrate for solution for infusion atezolizumab
Croatian: Tecentriq 1200 mg koncentrat za otopinu za infuziju atezolizumab
English: Myositis
Croatian: Miozitis
English: Prognostic risk factors included time from prior chemotherapy of < 3 months,
Croatian: Prognostički faktori rizika uključivali su vrijeme od prethodne kemoterapije < 3 mjeseca, funkcionalni ECOG status > 0 te vrijednost hemoglobina < 10 g/dl.
English: The median time to onset 7.2 months (range: 24 days to 13.7 months).
Croatian: Medijan vremena do nastupa iznosio je 7,2 mjeseca (raspon od 24 dana do 13,7 mjeseci).
English: Two patients required the use of corticosteroids.
Croatian: U dva je bolesnika bila potrebna primjena kortikosteroida.
English: Diabetes mellitus
Croatian: Šećerna bolest
English: Hypophysitis occurred in 0.8% (3/393) of patients who received atezolizumab with bevacizumab, paclitaxel, and carboplatin.
Croatian: Hipofizitis se javio u 0,8% (3/393) bolesnika koji su primali atezolizumab u kombinaciji s bevacizumabom, paklitakselom i karboplatinom.
English: • inflammation of the kidneys (nephritis); symptoms may include changes in urine output and color, pain in pelvis, and swelling of the body and may lead to failure of the kidneys
Croatian: • upalu bubrega (nefritis): simptomi mogu uključivati promjene u količini i boji mokraće, bol u zdjelici i oticanje tijela te mogu dovesti do zatajenja bubrega
English: Meningoencephalitis requiring the use of corticosteroids occurred in 0.2% (6/3,178) of patients receiving atezolizumab and four patients discontinued atezolizumab.
Croatian: Meningoencefalitis koji je zahtijevao primjenu kortikosteroida nastupio je u 0,2% (6/3178) bolesnika koji su primali atezolizumab, a četiri su bolesnika prekinula liječenje atezolizumabom.
English: Baseline ECOG performance status was 0 (37%) or 1 (63%).
Croatian: Početni funkcionalni ECOG status iznosio je 0 (37%) ili 1 (63%).
English: Grenzacherstrasse 124
Croatian: Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel
English: NE (11.1, NE)
Croatian: NP (11,1; NP)
English: The primary analysis of study IMvigor211 did not meet its primary endpoint of OS. Atezolizumab did not demonstrate a statistically significant survival benefit compared to chemotherapy in patients with previously treated, locally advanced or metastatic urothelial carcinoma.
Croatian: Atezolizumab nije pokazao statistički značajan koristan učinak na preživljenje u odnosu na kemoterapiju u bolesnika s prethodno liječenim lokalno uznapredovalim ili metastatskim urotelnim karcinomom.
English: • have been given a live, attenuated vaccine
Croatian: • ako ste primili živo atenuirano (oslabljeno) cjepivo
English: Treatment with atezolizumab must be permanently discontinued for Grade 3 or 4 pneumonitis.
Croatian: Liječenje atezolizumabom mora se trajno prekinuti u slučaju pneumonitisa 3. ili 4. stupnja.
English: Patients were randomised (1:1) to receive either atezolizumab or docetaxel.
Croatian: Bolesnici su bili randomizirani u omjeru 1:1 za primanje atezolizumaba ili docetaksela.
English: • feeling very tired (fatigue)
Croatian: • izražen umor (iscrpljenost)
English: Primary efficacy endpoint OS
Croatian: Primarna mjera ishoda za djelotvornost OS
English: For symptomatic hyperthyroidism, atezolizumab should be withheld and an anti-thyroid medicinal product should be initiated as needed.
Croatian: U slučaju simptomatske hipertireoze treba odgoditi primjenu atezolizumaba i po potrebi uvesti lijek koji potiskuje funkciju štitnjače.
English: Immune-related pancreatitis
Croatian: Imunološki uzrokovan pankreatitis
English: Figure 2: Kaplan-Meier curve for overall survival in the primary analysis population (all comers) (OAK)
Croatian: Slika 2: Kaplan-Meierova krivulja ukupnog preživljenja u populaciji za primarnu analizu (svi uključeni bolesnici) (OAK)
English: Figure 5: Forest plot of progression free survival by PD-L1 expression in the ITT population, Arm B vs. C (IMpower150)
Croatian: Slika 5: Grafikon raspona pouzdanosti za preživljenje bez progresije bolesti prema ekspresiji PD-L1 u ITT populaciji, skupina B naspram skupine C (IMpower150)
English: During the induction phase, the recommended dose of Tecentriq is 1,200 mg administered by intravenous infusion followed by carboplatin, and then etoposide administered by intravenous infusion on day 1.
Croatian: Tijekom faze uvodnog liječenja preporučena doza lijeka Tecentriq je 1200 mg intravenskom infuzijom, nakon koje se primjenjuje karboplatin, a zatim etopozid intravenskom infuzijom 1. dana.
English: Patients with previously untreated UC should be selected for treatment based on the tumour expression of PD-L1 confirmed by a validated test (see section 5.1).
Croatian: PD-L1 testiranje u bolesnika s urotelnim karcinomom Bolesnike s prethodno neliječenim urotelnim karcinomom potrebno je odabrati za liječenje na temelju tumorske ekspresije PD-L1 potvrđene validiranim testom (vidjeti dio 5.1).
English: Data from patients with severe renal impairment are too limited to draw conclusions on this population.
Croatian: Podaci o primjeni u bolesnika s teškim oštećenjem bubrežne funkcije previše su ograničeni da bi se na temelju njih donijeli zaključci za tu populaciju.
English: Treatment with intravenous corticosteroids (1 to 2 mg/kg/day methylprednisolone or equivalent) should be started.
Croatian: Treba uvesti liječenje intravenskim kortikosteroidima (1 - 2 mg/kg/dan metilprednizolona ili ekvivalenta).
English: + carboplatin (AUC 6)
Croatian: + karboplatinc (AUC 6)
English: Second-line treatment of non-small cell lung cancer
Croatian: Druga linija liječenja raka pluća nemalih stanica
English: Figure 11: Forest plot of overall survival by PD-L1 expression in the primary analysis population (OAK)
Croatian: Slika 11: Grafikon raspona pouzdanosti za ukupno preživljenje prema ekspresiji PD-L1 u populaciji za primarnu analizu (OAK)
English: Hepatitis led to discontinuation of atezolizumab in 6 (< 0.2%) patients.
Croatian: Hepatitis je doveo do prekida liječenja atezolizumabom u 6 (< 0,2%) bolesnika.
English: Atezolizumaba (1,200 mg) + bevacizumabd (15 mg/kg) + paclitaxel (200 mg/m2)b,c carboplatinc (AUC 6)
Croatian: Atezolizumaba (1200 mg) + bevacizumabd (15 mg/kg) + paklitaksel (200 mg/m2)b,c karboplatinc (AUC 6)
English: Arm B (Placebo + carboplatin + etoposide)
Croatian: Skupina B (placebo + karboplatin + etopozid)
English: No. of partial response (%)
Croatian: Broj bolesnika s djelomičnim odgovorom (%)
English: Patients were excluded if they had history of autoimmune disease, administration of a live, attenuated vaccine within 28 days prior to randomisation, administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medicinal product within 2 weeks prior to randomisation, active or untreated CNS metastases, clear tumour infiltration into the thoracic great vessels or clear cavitation of pulmonary lesions, as seen on imaging.
Croatian: U ispitivanje nisu bili uključeni bolesnici koji su imali autoimunu bolest u anamnezi, koji su primili živo atenuirano cjepivo unutar 28 dana prije randomizacije, koji su primili sistemske imunostimulatore unutar 4 tjedna ili sistemske imunosupresive unutar 2 tjedna prije randomizacije, koji su imali aktivne ili neliječene metastaze u središnjem živčanom sustavu (SŽS), kao ni oni koji su imali jasnu infiltraciju tumora u velike torakalne krvne žile ili jasnu kavitaciju plućnih lezija, vidljive na snimkama dobivenima oslikavanjem.
English: The median time to onset was 2.1 months (range 21 days to 15.7 months).
Croatian: Medijan vremena do nastupa iznosio je 2,1 mjesec (raspon od 21 dana do 15,7 mjeseca).
English: Median (months) (95% CI)
Croatian: Medijan trajanja PFS-a (mjeseci) 95% CI
English: For the recommended dose of 1680 mg: twenty-eight mL of Tecentriq concentrate should be withdrawn from two vials of Tecentriq 840 mg and diluted into a 250 mL polyvinyl chloride (PVC), polyolefin (PO), polyethylene (PE), or polypropylene (PP) infusion bag containing sodium chloride
Croatian: Za preporučenu dozu od 1680 mg: Potrebno je izvući 28 ml koncentrata lijeka Tecentriq iz dviju bočica lijeka Tecentriq od 840 mg i razrijediti ga ubrizgavanjem u polivinilkloridnu (PVC), poliolefinsku (PO), polietilensku (PE) ili polipropilensku (PP) infuzijsku vrećicu volumena 250 ml koja sadrži otopinu natrijeva klorida za injekciju od 9 mg/ml (0,9%).
English: Gastrointestinal disorders Very common nausea, vomiting, diarrhoear nausea, diarrhoear, constipation, vomiting
Croatian: Poremećaji probavnog sustava Vrlo često mučnina, povraćanje, proljevr mučnina, proljevr, konstipacija, povraćanje
English: Patients receiving treatment regimen B were able to crossover and receive atezolizumab monotherapy following disease progression.
Croatian: B mogli su nakon progresije bolesti prijeći u drugu skupinu i primati monoterapiju atezolizumabom.
English: POPLAR (GO28753): Randomised phase II trial in locally advanced or metastatic NSCLC patients previously treated with chemotherapy
Croatian: POPLAR (GO28753): Randomizirano ispitivanje faze II u bolesnika s lokalno uznapredovalim ili metastatskim NSCLC-om prethodno liječenih kemoterapijom
English: Figure 2: Kaplan-Meier curve for overall survival in the ITT population (IMpower150)
Croatian: Slika 2: Kaplan-Meierova krivulja ukupnog preživljenja u ITT populaciji (IMpower150)
English: • low platelet count, which may make you more likely to bruise or bleed
Croatian: • nizak broj trombocita, zbog čega možete biti skloniji nastanku modrica ili krvarenju
English: During the induction phase, the recommended dose of Tecentriq is 1,200 mg administered by intravenous infusion, followed by nab-paclitaxel and carboplatin every three weeks for four or six cycles.
Croatian: Tijekom faze uvodnog liječenja preporučena doza lijeka Tecentriq je 1200 mg intravenskom infuzijom, nakon koje se primjenjuju nab-paklitaksel i karboplatin svaka tri tjedna tijekom četiri ili šest ciklusa.
English: Infusion-related reactions have been observed with atezolizumab (see section 4.8).
Croatian: Kod primjene atezolizumaba primijećene su reakcije na infuziju (vidjeti dio 4.8).
English: • Description of the main signs and symptoms of the following safety concerns and reminder of the importance of notifying their treating physician immediately if symptoms occur, persist or worsen: Immune-Related Hepatitis Immune-Related Pneumonitis Immune-Related Colitis Immune-Related Pancreatitis
Croatian: • Opis glavnih znakova i simptoma sljedećih sigurnosnih problema te podsjetnik o važnosti da se odmah obavijesti nadležnog liječnika ako se takvi simptomi pojave, ako potraju ili ako se pogoršaju: imunološki uzrokovan hepatitis imunološki uzrokovan pneumonitis imunološki uzrokovan kolitis imunološki uzrokovan pankreatitis imunološki uzrokovane endokrinopatije (šećerna bolest tipa 1, hipotireoza, hipertireoza, insuficijencija nadbubrežne žlijezde i hipofizitis) imunološki uzrokovane neuropatije (Guillain-Barréov sindrom, mijastenički sindrom / miastenija gravis) imunološki uzrokovan meningoencefalitis imunološki uzrokovan miokarditis imunološki uzrokovan nefritis imunološki uzrokovan miozitis reakcije na infuziju
English: The median duration was 26 days (range 6 days to 14.5+ months; + denotes a censored value).
Croatian: Medijan trajanja iznosio je 26 dana (raspon od 6 dana do 14,5+ mjeseci; ‘+' označava cenzuriranu vrijednost).
English: Tumour assessments were conducted every 6 weeks for the first 36 weeks, and every 9 weeks thereafter.
Croatian: Procjene tumorskog odgovora provodile su se svakih 6 tjedana tijekom prvih 36 tjedana, a zatim svakih 9 tjedana.
English: IMpower150 (GO29436): Randomised phase III trial in chemotherapy-naïve patients with metastatic non-squamous NSCLC, in combination with paclitaxel and carboplatin with or without bevacizumab
Croatian: IMpower150 (GO29436): Randomizirano ispitivanje faze III provedeno u bolesnika s metastatskim neplanocelularnim NSCLC-om koji prethodno nisu primali kemoterapiju, u kombinaciji s paklitakselom i karboplatinom, uz bevacizumab ili bez njega
English: 4.7 Effects on ability to drive and use machines Tecentriq has minor influence on the ability to drive and use machines.
Croatian: 4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima
English: Placebo + nab-paclitaxel
Croatian: Placebo + nab-paklitaksel
English: No. of complete response (%)
Croatian: Broj bolesnika s potpunim odgovorom (%)
English: Pneumonitis led to discontinuation of atezolizumab in 12 (0.4%) patients.
Croatian: Pneumonitis je doveo do prekida liječenja atezolizumabom u 12 (0,4%) bolesnika.
English: b Includes reports of pneumonia, bronchitis, lung infection, lower respiratory tract infection, infective exacerbation of COPD, infectious pleural effusion, tracheobronchitis, atypical pneumonia, lung abscess, pyopneumothorax.
Croatian: Uključuje prijavljene slučajeve pneumonije, bronhitisa, infekcije pluća, infekcije donjih dišnih putova, egzacerbacije KOPB-a uzrokovane infekcijom, pleuralnog izljeva uzrokovanog infekcijom, traheobronhitisa, atipične pneumonije, plućnog apscesa i piopneumotoraksa.